

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method for ~~stabilizing an IgM-suppressing cryoprecipitation~~
of IgM in a solution at a temperature of 1°C to 7°C, wherein the method comprises adding a
citric acid buffer to a first solution comprising the IgM to form a second solution comprising the
IgM at a concentration of 20 mg/ml or greater, and maintaining the second solution at 1°C to
7°C, thereby ~~suppressing cryoprecipitation of stabilizing~~ the IgM.

2-3. (Canceled)

4. (Previously presented) The method of claim 1, wherein the pH of the second solution
is 5 to 8.

5. (Previously presented) The method of claim 1, comprising cooling the second
solution to a temperature of 7 °C.

6. (Previously presented) The method of claim 1, comprising cooling the second
solution to a temperature of 4 °C.

7. (Previously presented) The method of claim 1, comprising cooling the second
solution to a temperature of 1 °C.

8. (Previously presented) The method of claim 1, wherein the concentration of citric
acid buffer in the second solution is 1 mM to 500 mM.

9. (Previously presented) The method of claim 8, wherein the concentration of citric acid buffer in the second solution is 5 mM to 100 mM.

10. (Previously presented) The method of claim 9, wherein the concentration of citric acid buffer in the second solution is 10 mM to 50 mM.

11. (Previously presented) The method of claim 1, wherein the IgM is purified.

12. (Previously presented) The method of claim 1, comprising cooling the second solution to a temperature between 1 °C and 7 °C.

13. (Previously presented) The method of claim 1, wherein the second solution is maintained at a temperature of 1 °C.

14. (Previously presented) The method of claim 1, wherein the second solution is maintained at a temperature of 4 °C.

15. (Previously presented) The method of claim 1, wherein the second solution is maintained at a temperature of 7 °C.

16. (New) The method of claim 4, wherein the pH of the second solution is 5 to 6.

17. (New) The method of claim 1, wherein the concentration of the IgM in the second solution is 25 mg/ml or greater.

18. (New) The method of claim 1, wherein cryoprecipitation of IgM is suppressed 30% or more, expressed as a cryoprecipitation increase suppression rate.

19. (New) The method of claim 1, wherein cryoprecipitation of IgM is suppressed 50% or more, expressed as a cryoprecipitation increase suppression rate.

20. (New) The method of claim 1, wherein cryoprecipitation of IgM is suppressed 80% or more, expressed as a cryoprecipitation increase suppression rate.